Sign in
Stories
Aptose Biosciences Closes $9.7 Million Offering
Share
Aptorum Group's Annual General Meeting R...
Biopharma Companies Announce Public Offe...
Sustainability Champion: AptarGroup's Re...
AptarGroup: Sustaining Excellence
Aptiv PLC: 12 Years Ethical Excellence
Aptiv to Release Q4 2023 Financial Resul...
Overview
API
Aptose Biosciences closes a $9.7 million public offering of common shares and warrants led by Newbridge Securities Corporation and including a strategic investment by Hanmi Pharmaceutical. The net proceeds will support clinical trials for tuspetinib, manufacturing of tuspetinib clinical supplies, and working capital.
Ask a question
How does Aptose Biosciences' focus on precision medicines for hematologic malignancies differ from traditional approaches?
How might the strategic investment by Hanmi Pharmaceutical impact Aptose Biosciences' future developments?
What are the potential implications of the funding for the success of tuspetinib in clinical trials?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Jan 2024
Coverage